Sareum and Structure: An Interview with Tim Mitchell, CEO, Sareum
March 2007
Sareum and Structure: An Interview with Tim Mitchell, CEO, Sareum
Interview with Tim Mitchell
Sareum and Structure: An Interview with Tim Mitchell, CEO, Sareum
Fintan Walton talks to Tim Mitchell, CEO, Sareum, about founding the company with David Williams and John Reader, as a spin-out from Millennium Pharmaceuticals' Structure-based Discovery Department. Tim explains how the company's success is based on the excellent track record and relationships the management established at Millennium Pharmaceuticals and at Cambridge Discovery Chemistry and the efficient structure-based drug discovery services they have refined over the years.
About Tim Mitchell
Dr Tim Mitchell, has 18 years’ experience in the industry, with key management and business expertise gained from his positions at Cambridge Discovery Chemistry and his roles at Millennium, as a member of the management team and through forming the integrated Structure-Based Discovery Department.
As Director of the Millennium Structure-Based Discovery Department, Tim was responsible for global provision of protein structure and high-throughput chemical synthesis for Millennium as well as for local computational chemistry, informatics and automation capabilities. Prior to that, he was Director of Computational Chemistry at Cambridge Discovery Chemistry Ltd, and a team leader in the Computational and Structural Sciences department at SmithKline Beecham Pharmaceuticals. Tim has a PhD in Computational Chemistry and a BSc in Chemistry.
About Sareum
Sareum is an experienced and specialist structure-based drug discovery company that accelerates and improves the productivity of both in-house and partners' discovery research using its proprietary approaches.
With its highly experienced team, which has a track record of delivering high-quality results for pharmaceutical and biotechnology clients, Sareum is developing a robust pipeline of novel cancer drug candidates for partnering with pharmaceutical companies. The company generates revenues to support this pipeline through the provision of its specialist discovery research services. Sareum carries out complete structure-based discovery programmes for creating novel preclinical candidates as well as specific tailored projects to resolve clients' issues in gene-to-structure, structure-to-lead and/or lead-to-candidate activities.
Sareum creates novel IP and highly valuable clinical candidates for its clients across a range of therapeutic areas. The company is very flexible in its approach to how it structures its partnerships and can engage in fee-for-service, out-source research, technology transfer or joint research programmes.
Sareum is a publicly listed company and its shares are listed on the AIM market of the London Stock Exchange.
